July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant

June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 24, 2025

Best Fluid for Sepsis? Crystalloids Lead

A network meta-analysis of 32 randomized trials found that balanced crystalloid solutions were associated with lower mortality, reduced acute kidney injury, and shorter hospital stays in patients with sepsis or septic shock.

Conexiant

June 24, 2025

FDA Approves At-Home Lupus Nephritis Therapy

The FDA has approved a subcutaneous autoinjector of belimumab for at-home treatment of pediatric lupus nephritis.

Conexiant

June 11, 2025

8-Week Oral Therapy Approved for Acute HCV

The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention.

Conexiant

April 29, 2024

A Look Ahead at Rheumatology in 2024

A rheumatologist reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024.

Conexiant

November 11, 2024

Morning BP Rise Linked to Heart Hypertrophy

A morning BP rise of over 10 mmHg independently predicts left ventricular hypertrophy—accounting for 36.2% of LVMI variability, even after adjusting for age and BMI.

Conexiant

December 12, 2024

Brief, Vigorous Activity May Lower CV Risk in Women: Study Findings

A recent study shows that even 3.4 minutes of vigorous intermittent lifestyle physical activity per day could significantly reduce cardiovascular risk, particularly in non-exercising women.

Conexiant